- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00877500
전신 요법 후 HER2/Neu 음성 침습성 유방암의 유의미한 잔류 질환이 있는 참여자를 치료하는 익사베필론
HER2/Neu-음성 유방암에 대한 신보조적 전신 요법 후 상당한 잔여 질환이 있는 환자에서 익사베필론 대 관찰의 제2상 무작위 연구
This phase II trial studies how well ixabepilone compared with standard of care works in treating patients with HER2/Neu negative breast cancer that remains after undergoing systemic therapy. Ixabepilone works by blocking cell division which may cause cancer cell death.
연구 개요
상세 설명
PRIMARY OBJECTIVES:
I. To investigate the genomic (transcriptional profiles) and proteomic (pathway activation) features that distinguish tumors that do not achieve a pathologic complete response (pCR) after neoadjuvant systemic therapy (NST) and correlate these features with outcome in the presence and absence of adjuvant ixabepilone.
II. To evaluate the presence of circulating tumor cells (CTCs) at baseline (before chemotherapy starts; if radiation is used, after radiation ends), during and after ixabepilone therapy or during observation.
SECONDARY OBJECTIVES:
I. To collect serial blood samples for future pharmacogenomic studies. II. To determine if the addition of adjuvant ixabepilone will improve recurrence-free survival in patients that have significant residual HER 2/neu-negative breast cancer after NST.
III. To assess the toxicity of adjuvant ixabepilone in this group of patients.
OUTLINE: Participants are randomized to 1 of 2 groups.
GROUP I (IXABEPILONE): Participants receive ixabepilone intravenously (IV) over 3 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
GROUP II (STANDARD OF CARE): Participants receive standard of care for 18 weeks.
After completion of study treatment, participants are followed up every 3 months for 2 years and every 6 months for 3 years.
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
Illinois
-
Oak Lawn, Illinois, 미국, 60453-2699
- Advocate Christ Medical Center
-
-
Texas
-
Houston, Texas, 미국, 77030
- M D Anderson Cancer Center
-
Houston, Texas, 미국, 77026-1967
- Lyndon Baines Johnson General Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Patients with histologic confirmation of invasive HER2/neu-negative breast cancer (immunohistochemistry [IHC] 0-1+ or fluorescence in situ hybridization [FISH]-negative) that have received complete anthracycline and taxane neoadjuvant systemic therapy and that at the time of surgery are expected to have significant residual disease. Therapy should include at least 4 cycles of an anthracycline-based regimen (adriamycin-cytoxan [AC], 5-fluorouracil/adriamycin/intravenous [IV] cyclophosphamide [FAC], fluorouracil-epirubicin-IV cytoxan [FEC]) and 12 weeks of a taxane-based regimen (weekly paclitaxel, every 3-week docetaxel).
- Patients who did not complete therapy due to disease progression are eligible.
- Patients with bilateral breast cancers are eligible.
- Patients should have a Karnofsky performance scale of >= 70%.
- Peripheral granulocyte count of >= 1500/mm^3.
- Platelet count >= 100000 mm^3.
- Bilirubin within normal laboratory values.
- Alkaline phosphatase may be up to 1.5 x upper limit of normal (ULN) of the institution.
- Transaminases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) may be up to 1.5 x upper limit of normal (ULN) of the institution.
- Creatinine levels within normal range.
- Negative serum pregnancy test for a woman of childbearing potential.
- Women of childbearing potential (WOCP) must use a reliable and appropriate contraceptive method during the study and 6 months after chemotherapy is completed. Women of childbearing potential (WOCBP) are women who are not menopausal for 12 months or had no previous surgical sterilization.
- Patients must agree to have study tissue collections and blood sample collections.
- Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy.
- Patients should have their surgical tissues evaluated for residual cancer burden (RCB) and be used for correlative studies.
- Sexually active women of childbearing potential must use an effective method of birth control during the course of the study, in a manner such that risk of failure is minimized. Prior to study enrollment, women of childbearing potential (WOCBP) must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy. In addition, men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth control.
- All WOCBP MUST have a negative pregnancy test within 7 days prior to first receiving investigational product. If the pregnancy test is positive, the patient must not receive investigational product and must not be enrolled in the study. In addition, all WOCBP will be instructed to contact the Investigator immediately if they suspect they might be pregnant (e.g., missed or late menstrual period) at any time during study participation. The principal investigator (PI) will immediately notify BMS in the event of a confirmed pregnancy in a patient participating in the study.
Exclusion Criteria:
- Patients whose tumors express HER2 protein or have HER2/neu gene amplification.
- Patients with a history of other invasive malignancies diagnosed and treated within the previous 5 years, except non-melanoma skin cancer and non-invasive cervical cancer.
- Other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study (i.e., uncontrolled diabetes, uncontrolled hypertension, severe infection, severe malnutrition, unstable angina, or congestive heart failure - New York Heart Association Class III or IV, ventricular arrhythmias, active ischemic heart disease, myocardial infarction within six months, chronic liver or renal disease, active upper gastrointestinal [GI] tract ulceration).
- Patients with a pre-existing peripheral neuropathy > grade 1.
- Evidence of distant metastases.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Group I (ixabepilone)
Participants receive ixabepilone IV over 3 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. |
Given IV
다른 이름들:
|
|
활성 비교기: Group II (standard of care)
Participants receive standard of care for 18 weeks. |
Receive standard of care
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Genomic (transcriptional profiles) and proteomic (pathway activation) features that distinguish tumors
기간: Up to 5 years
|
RPPA will be used to objectively quantify (phospho)protein expression. Functional activation of the pathway will be defined as an increase in phosphorylation of at least one half of the components of each pathway above the median RPPA quantified activation across the entire tumor set. Data will be analyzed for the presence of clusters based on differential protein expression by using available methods with the R statistical software package. A variety of unsupervised clustering methods (including hierarchical clustering, K-means, independent component analysis, mutual information, and gene shaving) will be used to classify the samples into statistically similar groups. |
Up to 5 years
|
|
Significant circulating tumor cells (CTCs)
기간: At 18 weeks
|
Presence of any cell per 7.5 ml of whole blood. |
At 18 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of adverse events in each group
기간: Up to 5 years
|
Chi-square tests of independence and generalized logistic regression models will be used. |
Up to 5 years
|
|
Recurrence-free survival
기간: Up to 5 years
|
Will be estimated non-parametrically using the Kaplan-Meier product limit method. Cox proportional hazards regression models will be used to model recurrence-free survival as a function of treatment group. |
Up to 5 years
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Funda Meric-Bernstam, M.D. Anderson Cancer Center
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정된)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 2008-0435
- 2008-0435 (기타 식별자: M D Anderson Cancer Center)
- NCI-2018-01849 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .